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ABSTRAK
Latar belakang: penggunaan obat golongan statin untuk menurunkan kolesterol darah sering disertai 
efek samping yang mengganggu seperti mialgia dan gangguan fungsi hati. NC120 adalah obat herbal yang 
mengandung ekstrak ragi beras merah, guggulipid, dan chromium picolinat yang diharapkan tidak menimbulkan 
efek samping seperti statin. Penelitian ini bertujuan mengevaluasi efektivitas dan keamanan NC120 dalam 
menurunkan lipid darah. Metode: penelitian ini merupakan uji klinik dengan disain acak tersamar ganda, 
membandingkan NC120 dengan plasebo pada subjek dengan hiperkolesterolemia. NC120 atau plasebo diberikan 
dengan dosis 2 kapsul dua kali sehari selama 28 hari. Kadar kolesterol total, kolesterol LDL dan trigliserida 
diukur pada hari-0, hari-7, dan hari-28. Uji t-test tidak berpasangan digunakan untuk membandingkan 
parameter penelitian antar kelompok, sedangkan uji ANOVA satu arah digunakan untuk analisis dalam satu 
kelompok. Hasil: 25 subjek mendapat NC120 dan 24 subjek mendapat plasebo. Penurunan bermakna pada 
kadar kolesterol total dan kolesterol-LDL terlihat pada kelompok yang mendapat NC120, sedangkan pada 
kelompok plasebo tidak terlihat perbedaan bermakna. Tidak terlihat penurunan yang bermana pada kadar 
trigliserida pada kelompok NC120, maupun kelompok plasebo. Efek samping umumnya ringan dan seimbang 
pada kedua kelompok. Kesimpulan: NC120 efektif menurunkan kadar kolesterol total dan kolesterol-LDL, 
tapi tidak efektif menurunkan trigliserida. NC120 menunjukkan profil keamanan yang cukup baik, dan obat ini 
dapat dipertimbangkan  tidak bisa merekomendasikan sesuatu berdasar satu RCT apalagi jumlah sampel masih 
terbatas terutama untuk pasien hiperkolesterolemia yang tidak toleran terhadap statin.
Kata kunci: Nutrafor, kolesterol, ragi beras merah, guggulipid.
ABSTRACT
Background: the use of statin to lower blood cholesterol is often associated with bothersome adverse effects 
such as myopathy and liver dysfunction. NC120 is herbal lipid lowering drug containing red yeast rice (RYR) 
extract, guggulipid, and chromium picolinate, and expected to have better safety profile. The aim of this study was 
to evaluate the efficacy and safety profiles of NC120 in lowering blood lipid. Methods: this was a double blind 
randomized clinical trial comparing NC120 with placebo in subjects with hypercholesterolemia. Two capsules 
of NC120 or placebo were administered twice a day for 28 days. Blood total-cholesterol, LDL-cholesterol, and 
triglyceride were measured on day-0, day-7, and day-28. Unpaired t-test was used to compare study parameter 
between groups, and one-way ANOVA was used to compare within group. Results: 25 subjects received NC120 
and 24 subjects received placebo. Significant decrease of total cholesterol and LDL-cholesterol were observed 
since day-7 in NC120 group, while the changes in placebo group were not significant at all time of observation. 
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No significant decrease of triglyceride was observed in NC120 group and in placebo group. Side effects were 
minor and comparable between the two groups. Conclusion: NC120 is effective in reducing total cholesterol 
and LDL-cholesterol, but not triglyceride. This drug shows a good safety profile, and thus can be considered 
for patients who can not tolerate statin drugs.
Keywords: Nutrafor, cholesterol, red yeast rice, guggulipid.
INTRODUCTION
Data from the National Vital Statistics Report 
stated that cardiovascular disease is still the 
leading cause of mortality in the US in 2015.1 
Among cardiovascular death, coronary artery 
disease (CAD) represents the most common 
cardiovascular disease. Hypercholesterolemia 
is considered as the most important trigger 
of atherosclerotic formation.2 Lipid lowering 
agents, especially statin groups are noted to have 
pivotal role in CAD prevention. This drug class 
has been used since 1990, and should be given 
to patients during acute heart attack, as well as 
chronic maintenance treatment.3
Despite its efficacy, the use of statins is often 
associated with some adverse effects, such as 
myopathy and liver dysfunction. Myopathy 
ranges from muscle pain (myalgia), myositis, 
and very rarely a life-threatening rhabdomyolisis. 
Myopathy, in the form of muscle pain might be 
the most common complaints of patients taking 
statin and become the most common reason for 
discontinuation of therapy.4,5 Regarding the role 
of statin therapy in the prevention and treatment 
of coronary artery disease, alternative treatment 
should be found for those who can not tolerate 
statins. In this case, the use of natural products 
is hoped to be a good alternative due to its 
reputation of good safety profile.
NC120 is a food supplement with the 
indication to help reducing blood lipids.6 Every 
capsule of NC120 contains 375 mg Red Yeast 
Rice (RYR) extract (comparable to 0.32 mg 
lovastatin), Guggulipid extract 110 mg (11 
mg Guggulsterones), and 50 mg of chromium 
picolinate.6 Red Yeast Rice (RYR) contains 0.4% 
monacolin K which is identical with lovastatin 
and reported to exhibit a cholesterol-lowering 
action through inhibition of the HMG-CoA 
reductase. In addition, other components in RYR, 
such as plant sterols, isoflavones, selenium, and 
zinc, are also believed to have lipid lowering 
effects.7,8 The effects of guggulipid for cholesterol 
lowering are less clear and various studies 
showed variable effects. Chromium picolinate is 
a food supplement with antioxidant activity and 
often recommended for diabetic patients. A study 
by Press et al.9 reported a decrease in TC, LDL-
cholesterol and apolipoprotein B, and an increase 
in HDL-cholesterol and apolipoprotein A.
A mixture of the 3 ingredients in NC120 
has been marketed for reducing blood lipids. 
However, a formal clinical study has never 
been done. Therefore, this study was aimed to 
evaluate its efficacy as well as safety profile of 
NC120 in decreasing blood lipids in subjects 
with hypercholesterolemia.
METHODS
This was a double-blind randomized 
controlled clinical trial to compare NC120 versus 
placebo. This study was conducted at the Clinical 
Research Supporting Unit (CRSU), Faculty of 
Medicine, Universitas Indonesia, between March 
2016 to June 2018.
The protocol of this study has been approved 
by the Research Ethics Committee of the Faculty 
of Medicine, University of Indonesia with 
approval letter number 590/UN2.F1/ETIK/2015.
Inclusion Criteria
Included in this study were men or women 
aged 18 to 60 years with LDL cholesterol 
130 - 180 mg/dL, have never received lipid 
lowering drugs (including herbal or supplements) 
regularly within one month prior to the study, 
and willing to participate in the study by signing 
informed consent form. Those with the history 
of hypersensitive to any components of NC120, 
pregnant or lactating women, presence or a history 
of CV disease except grade 1 hypertension, 
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presence of diarrhea or inflammatory bowel 
syndrome, patients with liver dysfunction (ALT 
or AST > 3x ULN or a history of cirrhosis), 
patients with renal dysfunction (ClCr < 50 mL/
min), were excluded. 
Sample Size
This study was planned as a preliminary 
study. Thus, sample size was not calculated, 
and 2 x 30 evaluable patients were determined 
by the investigator. However, after an interim 
analysis, it turned out that the minimum sample 
size needed per group was only 25.
Study Drugs
NC120 and placebo capsules were prepared 
by Novell Pharmaceutical Laboratories, and 
presented as identical capsule with similar 
colour. Allocation of patients to receive either 
products was done by random permutation 
blocks of size 4. Packaging product for individual 
patients was done by the Clinical Study Unit, 
Faculty if Medicine, Universitas Indonesia 
according to a pre-determined randomization 
list. Each drug package was labelled with the 
patient randomization number and dosage 
instruction. Each patient received drug supply for 
consumption during each period between visits 
plus a few days in excess, for compliance check 
and to allow additional days for patient visit.
Drug Administration
After 2 weeks run-in period, each patent 
received either NC120 (NC) or Placebo, in a 
double-blind fashion, to be taken 2 capsules in 
the morning after breakfast and 2 capsules in the 
evening after dinner, for a duration of 4 weeks. 
Concomitant Medication
Use of chronic medications for other chronic 
diseases (eg. hypertension) was allowed if the 
use started more than 2 weeks prior to screening 
and the dose remained constant throughout the 
whole study.
Efficacy Assessments
Total cholesterol, LDL-cholesterol, and 
triglyceride were measured as parameters of 
efficacy at day-0 (before treatment), day-7, and 
day-28 of the study.
Data Analyses
The efficacy analysis was done as intent-to-
treat (ITT) on all randomized patients without 
eligibility violation, who took at least one dose 
of study drug and returned at least once post-
randomization.
Statistical tests was used to compare the 
decrease of LDL-C, TC, and TG from baseline 
following therapeutic response to NC and 
Placebo after 7 days and 28 days. Paired-t or 
Wilcoxon test was used to analyze the difference 
from baseline within each group (NC120 and 
Placebo), and unpaired-t or Mann-Whitney test 
was used to analyze the difference from baseline, 
at day 7 and 28 between NC and Placebo.
Safety analysis. All patients who took at least 
one dose of the study drug and returned at least 
once post-randomisation, were subject to safety 
analysis. All adverse events were listed per group 
(NC and Placebo), both the incidence and the 
percentage. The adverse events with possible 
and probable relationship to the study drug 
(ADRs) were also listed as the incidence and 
the percentage per group (NC120 and Placebo). 
Role of Funding Source and the Authors
This study was funded by PT Novell 
Industries. Nafrialdi was the principle investigator 
and wrote the final report; Frans D. Suyatna and 
Johannes Hudyono were the co-investigators; and 
Arini Setiawati made the protocol and had some 
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1 dropped out
163 screened
Figure 1. Recruitment of subjects during the study of NC120
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RESULTS
A total of 163 subjects were screened, 
but most of them failed to meet the inclusion 
criteria after run-in period of 2 weeks. Thus, 
only 50 subjects were eligible to enter the 
study. Twenty six subjects received NC120 and 
24 received placebo. One subject in NC120 
group was dropped-out due to unnoticed age 
that exceeded 60 year (Figure 1). Both groups 
were comparable in demography and baseline 
characteristics (Table 1).
Table 1 shows demographic and baseline 
characteristics of patients. It can be seen that 
booth groups are comparable in almost every 
parameter.
Efficacy Analysis
NC120 showed significant decreases in total 
cholesterol and LDL-cholesterol since the first 









 - Male 8 (32.0%) 9 (37.5%)
 - Female 17 (68.0%) 15 (62.5%)
Age (yrs), Mean (SD) 44.6 (9.25) 44.8 (8.95)
Weight (kg), Mean 
(SD) 68.8 (12.56) 64.9 (14.08)
Height (cm), Mean 
(SD) 155.6 (7.10) 155.6 (8.80)
BMI (kg/m2), Mean 
(SD) 28.4 (4.91) 26.6 (3.79)
Baseline characteristics
SBP (mmHg) 121.5 (15.70) 117.9 (16.88)
DBP (mmHg) 80.0 (9.35) 75.6 (9.48)
Heart rate (beats/min) 71.3 (8.20) 75.8 (8.67)
Haemoglobin (g/dL) 13.9 (1.62) 13.9 (1.39)
Hematocrit (%) 41.6 (3.93) 41.7 (3.80)
Platelet (103/mL) 305.8 (94.44) 320.4 (72.29)
Leukocyte (103/mL) 7.6 (1.54) 8.0 (1.98)
Ureum (mg/dL) 18.4 (9.61) 17.7 (6.49)
Creatinine (mg/dL) 0.78 (0.17) 0.71 (0.19)
AST (U/L) 26.2 (11.70) 25.9 (16.29)
ALT (U/L) 28.2 (21.91) 25.3 (21.79)
Total chol. (mg/dL) 214.5 (23.55) 214.6 (30.81)
LDL-C (mg/dL) 149.6 (15.98) 155.0 (14.10)
Triglyseride (TG)  
(mg/dL) 149.5 (69.40) 148.1 (71.71)
week of treatment, whereas placebo did not. 
Meanwhile, effect of NC120 on triglyceride was 
small and not significant (Figure 2).
Figure 2. Effects of NC120 on serum levels of Total 
cholesterol, LDL-cholesterol, and triglyceride on D-0, D-7, 
and D-28. (*: p < 0.05 vs D-0).
Table 2 shows the data on adverse events 
during this study. There was no subject undergoing 
serious adverse event, while non-serious adverse 
events were experienced by almost same number 
of patients receiving NC120 (28%) or placebo 
(29.1%).
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Safety Analysis that of Becker’s. Our study was conducted on 
naïve patient while the study of Becker was done 
on patients who have failed statin therapy due 
to myalgia side effect. Dietary restriction was 
implicated in the study of Becker, while the diet 
of the patients in our study remained as usual. In 
addition, NC120 also contains guggulipid which 
was reported to have lipid lowering effect.10
Another clinical trials reported that red yeast 
rice product should contain substantial amount of 
monakalin K to have significant lipid lowering 
effect. While some red yeast rice products on 
the market contain very little of monakalin K.11 
Each capsule of NC120 contains monakalin K 
comparable to 0.32 g lovastatin. This amount is 
indeed very small compared to therapeutic dose 
of lovastatin. It can be assumed that mechanisms 
other than HMG-CoA reductase inhibition, may 
have participated in the effect of NC120. This 
assumption is supported by the fact that many 
red yeast rice products also contain very small 
of monakalin K, yet show significant effect on 
blood cholesterol.11 One of the aims of using 
herbal products is to avoid adverse effects such 
as myalgia and liver dysfunction as commonly 
encountered with statin drugs. In our study, no 
patients showed these adverse effects. We did 
not measure the creatine phosphokinase (CPK), 
but no subject complaining of myalgia, nor 
elevation of liver enzymes during 4 weeks of 
treatments. This finding was supported by the 
study of Becker et al,10 that no increase of CPK 
after treatment with red yeast rice product. This 
confirms the safety profile of NC120 and that 
this herbal drug is suitable for those who are 
intolerant to statin drugs.
Other compositions of NC120 are guggulipid 
and chromium picolinate. Guggulipid is a resin 
of the Commiphora mukul tree and well known 
as guggulsterone. It has been used since more 
than 2000 years in Ayurvedic medicine to heal 
many kinds of diseases. The stereoisomers E- 
and Z-guggulsterone have been identified as the 
active agents in this resin. With sequestration 
effect on bile acid, guggulsterone is assumed 
to inhibit lipid emulsification in the intestine, 
and thus, block lipid absorption. Clinical 
study has shown that guggulipid 2 x 50 mg/
day significantly lowered blood cholesterol 
Table 2. List of adverse events and adverse drug reactions 
related to study product.
Adverse Event NC120 (n = 25) Placebo (n = 24)
Polyuria 0 1









Total 7 (28.0) 7 (29.1)
DISCUSSION
NC120 is a herbal product containing 
combination of Red Yeast Rice (RYR) extract 375 
mg (comparable to 0.32 mg lovastatin), guggulipid 
extract 110 mg (11 mg Guggulsterones), and 
chromium picolinate 50 mg.6 It represents an 
alternative lipid lowering agent for those are 
intolerant to statin drugs, either due to myalgia 
or liver dysfunction. The results of this study 
showed that NC120 started to lower total 
cholesterol and LDL-cholesterol significantly 
since day-7 of treatment. Continuation of the 
treatment until day-28, further decreased the 
lipid level, although not significantly different 
from day-7. It seems that optimal effect has 
already been achieved within one or two weeks 
of treatment. This effect is comparable to statin 
which begin to decrease LDL within two weeks. 
Red Yeast Rice in NC120 contains monakalin K 
which is comparable to 0.32 mg of lovastatin. 
Since the lovastatin content is small, it may 
contribute albeit small, to the lipid lowering 
action of RYR. 
Becker et al.10 reported that RYR extracts was 
effective in reducing blood cholesterol without 
increasing myalgia and creatine phosphokinase 
(CPK) in statin intolerant patients.9 This 
group reported a significant decrease in blood 
cholesterol at week 12 of treatment, whereas 
in our study, the decrease of blood cholesterol 
was observed much earlier. Explanation of this 
difference was not clearly known, but some 
differences are found between our study and 
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compared to placebo.12 Another study reported 
a decrease of total cholesterol level by 13% 
and triglyceride level by 12% after 12 weeks 
of treatment.13 In our study, NC120 contains 
110 mg of guggulipid, and the dose used was 2 
capsules twice daily. It means that the dose of 
guggulipid in our study is more than four times 
of the previous study.13 This might explain why 
the effect on cholesterol can be observed much 
earlier in our study.
Chromium picolinate is a chemical substance 
that frequently used for diabetic patients. It has 
some metabolic effects on carbohydrate and lipid 
metabolism, as well as other beneficial effect on 
hormonal disorder, including polycystic ovary 
syndrome (PCOS).14
We did not observe significant effect of 
NC120 on triglyceride level. On the contrary, 
a greater decrease of triglyceride was observed 
in placebo group compared to NC120 group, 
although the difference was not statistically 
significant. Explanation of this discrepancy is not 
known, but the possible arbitrary changes could 
not be ruled out. Therefore, it may be concluded 
that the mechanism of action of NC120 in 
lowering total cholesterol and LDL-cholesterol 
was a mixture of inhibition of HMG-CoA 
reductase (a small part) and mostly by blocking 
lipid absorption by gugglesterone. 
Chromium picolinate (CrPic) is another 
active component found in NC120. This 
substance is frequently used in many food 
supplements owing to its various effects 
including antioxidant, some positive effects 
in carbohydrate and lipid metabolism.15 Some 
animal studies reported its effects in lipid 
metabolism. Its mechanisms in improving lipid 
profile is not clear. But, it is assumed to derived 
from its stimulatory effect on 5-AMP kinase, 
and subsequently suppresses sterol regulatory 
element binding protein (SREBP-1). In addition, 
CrPic also has inhibitory effect on acetyl Ca-
carboxylase, expected to decrease the activity of 
malony-CoA, an enzyme involved in choleterol 
synthesis.15
During this study, 7 out of 25 patients (28%) 
in NC120 group and 7 out of 24 patients (29.1%) 
in placebo group reported some subjective 
adverse events, including gastric pain, nausea, 
itching, and sleepy. It can be said that the 
percentage of adverse events is quite identical 
in both groups. No influence of these adverse 
events on the continuation of the treatment. 
Typical side effect of statin group in the form of 
myalgia and myopathy was not found during the 
treatment with NC120. Laboratory parameters 
of organ function, including peripheral blood 
count, serum tranaminase, and serum creatinine 
were not different between NC120 and placebo 
group. It can be concuded that NC120 has a good 
safety profile.
A pilot study with sample size of 30 patients 
in each group was planned at the beginning 
of the study. However, after recruiting 163 
patients, most of the subjects had LDL level 
below inclusion criteria after run-in period of 2 
weeks. Indeed, the recruitment of subjects was 
very slow, therefore an interim analysis was 
performed during the study in order to obtain 
some data for calculating sample size needed to 
have 80% of study power. It turned out that the 
minimum sample size needed for each group is 
only 25. Thus, this study was terminated after 
reaching that number of subjects.
CONCLUSION
This study showed that NC120 is effective 
in reducing blood cholesterol (total-cholesterol 
and LDL-cholesterol) since the first week 
of treatment, without significant effects on 
triglyceride. This drug seems to have a good 
safety profile with the incidence of adverse effect 
comparable to placebo. Based on these results, 
NC120 could be considered as an alternative for 
statin-intolerant patients. However, considering 
that the actual use would be for a much longer 
time, more data is needed to assure the safety for 
longtime usage.
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